CAS: 33693-48-0; (4-(Benzyloxy)-3-Methoxyphenyl)Methanol

该化合物是一种有机化合物,其特点是芳香结构,其中包括苯基酒精混合物和苯环上的两个替代物;一个苯氧基和甲氧基混合物组的存在有助于其化学特性,包括其在有机溶剂中的溶性以及各种化学反应中的潜在反应性;该化合物一般具有中度极性,因为氢氧基组可以从事氢结合,增强极地溶剂的溶性;此外,甲基氧基化合物组可以影响芳基环的电子特性,有可能影响其在电子哲学替代反应中的再活动;该混合物还可能显示生物活动,使其对医药化学和药理感兴趣;其合成通常涉及标准的有机反应,例如醚化和减少过程;总体而言,4-(苯基氧基)-3-甲基乙氧基苯基苯丙酰律醇是一种多种化合物,在有机化学领域的研究和发展中应用.

结构式图片

上下游产品

CAS号2426-87-1 4-苄氧基-3-甲氧基苯甲醛 | CAS号498-00-0 香草醇 | CAS号100-39-0 溴化苄 | CAS号121-33-5 香草醛 | CAS号100-44-7 氯化苄 | CAS号498-00-0 香草醇 | CAS号222622-96-0 1-bromo-2-(brom... | CAS号2426-87-1 4-苄氧基-3-甲氧基苯甲醛 | CAS号169137-67-1 (4-benzyloxy-2-... | CAS号1860-57-7 2-(3-甲氧基-4-苯基甲氧... | CAS号580-72-3 罗汉松树脂酚 | CAS号122-48-5 姜酮; 4-(4-羟基-3-甲... | CAS号33688-50-5 4-(chloromethyl... | CAS号1700-29-4 4-苯甲氧基-3-甲氧基苯基乙腈 | CAS号22231-61-4 4-苄氧基-3-甲氧基苯乙胺

合成工艺路线路线简述

    2-[(3-Methoxy-4-Phenylmethoxyphenyl)Methoxy]Oxane置于β-环糊精 水体系中,用 甲醇 作为反应溶剂,化学反应 9.0H,以86%的收率获得产物4-苄氧基-3-甲氧基苯甲醇
    参考文献:β-环糊精在水中对四氢吡喃基醚的选择性脱保护
    标题:β-环糊精在水中对四氢吡喃基醚的选择性脱保护
    摘要:这 水解 四氢吡喃基醚 酒类β-环糊精催化的过程水 在中性条件下.
    DOI:10.1039/b009187L

    海关参考信息

    专利信息


    专利号:US-7365197-B2
    优先权日:2000-12-29
    标题 :Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
    发明人:BERGER DAN MAARTEN; BIRNBERG GARY HAROLD; WANG YANONG
    权利人:WYETH CORP
    摘要:This invention relates to a method for the regioselective synthesis of 4,6,7,8-substituted benzo[g]quinoline-3-carbonitriles and 4,6,7,8-substituted benzo[g]quinazolines as well as intermediates thereof. The compounds derived from this invention are useful for the treatment of a variety of diseases that are a result of deregulation of these PTK's, and more specifically, are anti-cancer agents and are useful for the treatment of cancer in mammals. In addition, the compounds derived from this invention are useful for the treatment of polycystic kidney disease in mammals.

    专利号:US-2014142279-A1
    优先权日:2012-09-13
    标 题:Method for peptide synthesis
    发明人:LALEZARI IRAJ; LALEZARI PARVIZ
    权利人:LALEZARI IRAJ; LALEZARI PARVIZ
    摘要:A new method based on the synthesis and use of novel N and C protecting agents. The new N-protecting agent, here referred to as V-Phenol, generates V-protected amino acids and can be successfully applied to all conventional peptide bond formations including active esters, N,N′-dicyclohexylcarbodiimide (DCC) or related dehydrating agents mixed anhydride methods, PC13 and related agents. The new C-protecting agent, here referred to as HONE, can be successfully applied to peptide synthesis as an active ester not only in combination with V-protected amino acids but also with other N-protecting agents such as Cbz, Boc, Fmoc, etc.

    专利号:US-7825149-B2
    优先权日:2006-01-19
    标 题 :Substituted imidazoles
    发明人:CHUBB NATHAN ANTHONY LOGAN; COX MARK ROGER; DAUVERGNE JEROME SEBASTIEN; EWIN RICHARD ANDREW; LAURET CHRISTELLE
    权利人:PFIZER LTD
    摘要:This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    宜兴市金兰化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:051087559010👤
    ⚠️参考联系方式
    邮件:981433861@qq.com
    销售经理: 陆苏君经理
    联系电话:86-051087559010
    手机号码: 15251402899
    传真号码: 86-051087587009
    QQ号:981433861
    江苏省宜兴市芳桥镇龙珠路
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    江苏省宜兴市芳桥镇龙珠路
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1186/s12906-023-04016-6
    摘要:Thongsom S, Racha S, Petsri K, Ei ZZ, Visuttijai K, Moriue S, Yokoya M, Chanvorachote P. Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway. BMC Complement Med Ther. 2023 Jun 03;23(1):183.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知